CN119837832A - Ultrasound responsive lipid drug carrier capable of percutaneous administration and preparation method thereof - Google Patents
Ultrasound responsive lipid drug carrier capable of percutaneous administration and preparation method thereof Download PDFInfo
- Publication number
- CN119837832A CN119837832A CN202510057442.8A CN202510057442A CN119837832A CN 119837832 A CN119837832 A CN 119837832A CN 202510057442 A CN202510057442 A CN 202510057442A CN 119837832 A CN119837832 A CN 119837832A
- Authority
- CN
- China
- Prior art keywords
- lipid
- drug
- ultrasound
- drug carrier
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides an ultrasound responsive lipid drug carrier capable of percutaneous administration and a preparation method thereof, wherein the method comprises the steps of dissolving lipid and surfactant in an organic solvent, and then removing the organic solvent by rotary evaporation to form a lipid film, adding an aqueous solution to hydrate the film, and finally adding an ultrasonic response substance to obtain the ultrasonic response lipid drug carrier capable of transdermal drug delivery. The lipid drug carrier is nano-scale, has good deformability and ultrasonic responsiveness, and is suitable for skin delivery and deep administration of water-soluble or fat-soluble drugs. The lipid drug carrier is combined with ultrasound, so that a drug delivery system capable of realizing deep percutaneous drug delivery in a noninvasive manner can be formed, and the problems of low drug delivery efficiency, poor safety, insufficient drug penetration depth and the like in the prior art can be effectively solved.
Description
Technical Field
The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to an ultrasonic responsive lipid pharmaceutical carrier capable of percutaneous administration and a preparation method thereof.
Background
Transdermal administration is the third largest route of administration, which is inferior to oral administration and injection administration, and has the advantages of reducing fluctuation of drug concentration in blood, reducing toxic and side effects, convenient administration, good patient compliance and the like, and the synergy strategies thereof are divided into passive administration and active administration. Passive administration is mainly classified into two types, chemical penetrants are used for breaking skin barrier to promote penetration, toxicity is high, skin irritation is possibly caused, and a certain risk exists, and a drug carrier can be used for encapsulating water-soluble or fat-soluble drugs, such as liposome, nano-particles, nano-emulsion and the like, but the administration efficiency is low when the drug carrier is used alone. Active administration refers to the use of physical methods to facilitate drug permeation, such as iontophoresis, lasers, microneedles, ultrasound, etc., which are intended to effectively disrupt the stratum corneum barrier using external energy, increasing the efficiency of drug penetration through the stratum corneum. The combination of passive and active methods may allow for more efficient administration than a single mode of administration. However, the current efficiency of the combined administration mode does not meet the clinical application requirements. In addition, existing approaches are primarily directed to the stratum corneum, and once the drug penetrates the stratum corneum barrier, how to control its subsequent transport and deep dermal delivery has not been addressed. In the existing method, the drug penetration depth is insufficient and is more below 500 μm when combined with iontophoresis or laser administration, and when the delivery depth exceeds 960 μm, obvious pain is caused, and when the delivery depth exceeds 1450 μm, bleeding and infection risks occur. Some diseases requiring deep dosing are not met.
Therefore, there is a need for more efficient, safe, and controllable transdermal delivery methods to achieve efficient, sufficient and deep delivery of drugs, providing a new strategy for transdermal drug delivery treatment of more clinical diseases.
Disclosure of Invention
The technical problem to be solved by the invention is to provide a lipid drug carrier with ultrasonic response which can stably encapsulate ultrasonic response substances, has good deformability and ultrasonic response, and can realize the aim of high-efficiency, sufficient and deep percutaneous drug delivery.
In order to solve the technical problems, the invention adopts the following technical scheme:
A method of preparing a transdermally administrable ultrasound-responsive lipid drag carrier, the method comprising the steps of:
s1, dissolving lipid and a surfactant in an organic solvent, and uniformly mixing to obtain a mixed solution;
S2, placing the mixed solution obtained in the step S1 in a rotary evaporator, and removing the organic solvent under a vacuum condition to form a lipid film;
S3, adding a hydration solution into the lipid film obtained in the step S2, and standing for 8-16 hours to hydrate the film to obtain a hydrated film;
S4, placing the hydrated film obtained in the step S3 in an ice bath, performing ultrasonic treatment for 2-10 min under the condition of power of 30-150W to form a lipid drug carrier, then adding an ultrasonic response substance, continuing ultrasonic treatment for 2-10 min, filtering the obtained solution through a polycarbonate membrane to obtain the ultrasonic response lipid drug carrier capable of being subjected to transdermal drug delivery, and preserving at the temperature of lower than 4 ℃.
Preferably, the lipid in S1 is one or more of phosphatidylcholine, phosphatidylethanolamine or phosphatidylglycerol;
Preferably, the surfactant in S1 is one of Span 80, span 20, tween 80, tween20, sodium cholate or sodium deoxycholate, and can improve the flexibility of the lipid membrane so as to enable the lipid membrane to have good deformability to pass through the stratum corneum barrier.
Preferably, the mass ratio of the lipid to the surfactant in the S1 is 70:30-95:5.
Preferably, the organic solvent in S1 is one or more of chloroform, methanol, ethanol or dichloromethane.
Preferably, the temperature of the rotary evaporator in the step S2 is 30-70 ℃ and the rotating speed is 60-90 rpm.
Preferably, the hydration solution in S3 is deionized water or phosphate buffer.
Preferably, the ultrasonic response substance in the step S4 is perfluorocarbon, in particular one or more of perfluoropentane and perfluorohexane, and the adding amount is 1 (5-100) according to the volume ratio of perfluorocarbon to the hydration solution.
Preferably, when the drug administration is a water-soluble drug, the water-soluble drug is dissolved in the hydration solution of step S3.
Preferably, when the drug administration is a fat-soluble drug, the fat-soluble drug is dissolved in the organic solvent of step S1.
The invention also provides an ultrasound responsive lipid drug carrier which can be used for transdermal drug delivery and is prepared by the method.
The invention also provides application of the transdermal ultrasound responsive lipid drug carrier, which can be used for skin delivery and deep administration of water-soluble or fat-soluble drugs.
The invention has the remarkable technical effects due to the adoption of the technical scheme:
1. the invention provides a nanoscale lipid drug carrier suitable for transdermal drug delivery, which can stably encapsulate an ultrasonic response substance and has good deformability and ultrasonic response, and the lipid drug carrier is combined with ultrasonic energy to realize deep skin delivery of drugs in a noninvasive and safe manner, so that the problems of low drug delivery efficiency, poor safety, insufficient drug penetration depth and the like in the prior art are effectively solved.
2. The invention combines the lipid drug carrier with ultrasound, shows better ultrasound responsiveness, and forms a drug delivery system capable of realizing deep percutaneous drug delivery in a noninvasive manner. Firstly, the deformability of the lipid drug carrier is utilized, the complete structure can be maintained under the drive of a hydration gradient, the epidermis is efficiently penetrated, and the stratum corneum structure is not damaged. And then applying ultrasound to trigger an ultrasonic response substance in the drug carrier to generate liquid-gas phase change, namely, the ultrasonic response substance is converted from a liquid state to a gas state, so that expansion is enlarged, and finally, the drug carrier is broken, and the drug is pushed to be further diffused into the deep dermis from the internal supplementary energy supply through micro-jet and mechanical friction effect generated after the ultrasonic action on the drug carrier, so that the aim of delivering a large amount of drug to the deep dermis is fulfilled, and the response intensity can be regulated by controlling the amount of the ultrasonic response substance (PFP) and ultrasonic parameters, so that the safety is ensured.
The invention is described in further detail below with reference to the drawings and examples.
Drawings
FIG. 1 is a transmission electron microscope image of an ultrasound responsive lipid drug carrier useful for transdermal administration in example 4 of the present invention;
FIG. 2 is a graph showing the particle size distribution of an ultrasound responsive lipid drug carrier useful for transdermal administration in example 4 of the present invention;
FIG. 3 is a graph of particle size and zeta potential change over seven days for an ultrasound responsive lipid drug carrier useful for transdermal administration in example 4 of the present invention;
fig. 4 is an optical image of an ultrasound responsive lipid drug carrier useful for transdermal drug delivery at various ultrasound irradiation times in example 4 of the present invention.
Detailed Description
Example 1
The embodiment is a method for preparing an ultrasound responsive lipid drug carrier capable of percutaneous administration, wherein the drug is fat-soluble drug triamcinolone acetonide, and the method comprises the following steps:
s1, dissolving 34mg of phosphatidylcholine and 6mg of Tween 20 in 18mL of dichloromethane, and then adding 25mg of triamcinolone acetonide for uniform mixing to obtain a mixed solution;
S2, adding the mixed solution obtained in the step S1 into a round-bottom flask, then placing the round-bottom flask into a rotary evaporator, and operating under vacuum conditions with the temperature of 55 ℃ and the rotating speed of 90rpm until the organic solvent is volatilized and removed, and forming a lipid film at the bottom of the round-bottom flask;
S3, adding 10mL of phosphate buffer solution (PBS solution, pH 7.4) into the lipid film obtained in the step S2, standing for 12h, and hydrating the film to obtain a hydrated film;
S4, placing the hydrated film obtained in the step S3 in an ice bath, performing ultrasonic treatment for 5min under the condition of 120W of power to form a lipid drug carrier, then adding 200 mu L of perfluoropentane and 200 mu L of perfluorohexane (1:1, v/v), continuing ultrasonic treatment for 5min, filtering the obtained solution through a polycarbonate film to obtain the ultrasonic response lipid drug carrier capable of being subjected to transdermal drug delivery, and preserving at the temperature lower than 4 ℃.
The particle size of the transdermally administrable ultrasound-responsive lipid drug carrier obtained in this example was 200nm.
Example 2
The embodiment is a method for preparing an ultrasound responsive lipid drug carrier capable of percutaneous administration, wherein the drug is fat-soluble drug triamcinolone acetonide, and the method comprises the following steps:
s1, dissolving 12mg of phosphatidylcholine and 3mg of Tween 80 in a mixed solvent of 8mL of chloroform and 4mL of methanol, and then adding 20mg of triamcinolone acetonide for uniform mixing to obtain a mixed solution;
S2, adding the mixed solution obtained in the step S1 into a round-bottom flask, then placing the round-bottom flask into a rotary evaporator, and operating under vacuum conditions with the temperature of 70 ℃ and the rotating speed of 65rpm until the organic solvent is volatilized and removed, and forming a lipid film at the bottom of the round-bottom flask;
s3, adding 8mL of PBS (phosphate buffer solution) into the lipid film obtained in the step S2, standing for 8 hours, and hydrating the film to obtain a hydrated film;
S4, placing the hydrated film obtained in the step S3 in an ice bath, performing ultrasonic treatment for 4min under the condition of 90W power to form a lipid drug carrier, then adding 300 mu L of perfluoropentane, continuing ultrasonic treatment for 4min, filtering the obtained solution through a polycarbonate membrane to obtain an ultrasonic response lipid drug carrier capable of being subjected to transdermal administration, and preserving at the temperature lower than 4 ℃.
The particle size of the transdermally administrable ultrasound-responsive lipid drug carrier obtained in this example was 210nm.
Example 3
This example is a method for preparing an ultrasound responsive lipid drug carrier for transdermal administration, the drug being the water soluble drug 5-fluorouracil (5-FU), comprising the steps of:
s1, dissolving 15mg of phosphatidylethanolamine, 3mg of cholesterol and 3mg of sodium cholate in 8mL of chloroform, and uniformly mixing to obtain a mixed solution;
s2, adding the mixed solution obtained in the step S1 into a round-bottom flask, then placing the round-bottom flask into a rotary evaporator, and operating under vacuum conditions with the temperature of 60 ℃ and the rotating speed of 60rpm until the organic solvent is volatilized and removed, and forming a lipid film at the bottom of the round-bottom flask;
S3, adding 10mL of PBS solution containing 2%5-FU (w/v) into the lipid film obtained in the S2, standing for 16h, and hydrating the film to obtain a hydrated film;
S4, placing the hydrated film obtained in the step S3 in an ice bath, performing ultrasonic treatment for 6min under the condition of 150W power to form a lipid drug carrier, then adding 200 mu L of perfluorohexane, continuing ultrasonic treatment for 6min, filtering the obtained solution through a polycarbonate membrane to obtain an ultrasonic response lipid drug carrier capable of being subjected to transdermal administration, and preserving at the temperature lower than 4 ℃.
The particle size of the transdermally administrable ultrasound-responsive lipid drug carrier obtained in this example was 180nm.
Example 4
This example is a method for preparing an ultrasound responsive lipid drug carrier for transdermal administration, the drug being the water soluble drug 5-fluorouracil (5-FU), comprising the steps of:
s1, dissolving 20mg of phosphatidylcholine and 5mg of Span 80 in a mixed solvent of 12mL of chloroform and 4mL of methanol, and uniformly mixing to obtain a mixed solution;
S2, adding the mixed solution obtained in the step S1 into a round-bottom flask, then placing the round-bottom flask into a rotary evaporator, and operating under vacuum conditions with the temperature of 60 ℃ and the rotating speed of 80rpm until the organic solvent is volatilized and removed, and forming a lipid film at the bottom of the round-bottom flask;
s3, adding 15mL of deionized water containing 1% of 5-FU (w/v) into the lipid film obtained in the step S2, standing for 12h, and hydrating the film to obtain a hydrated film;
S4, placing the hydrated film obtained in the step S3 in an ice bath, performing ultrasonic treatment for 6min under the condition of power of 60W to form a lipid drug carrier, then adding 150 mu L of perfluoropentane, continuing ultrasonic treatment for 4min, filtering the obtained solution through a polycarbonate membrane to obtain an ultrasonic response lipid drug carrier capable of being subjected to transdermal administration, and preserving at the temperature of lower than 4 ℃.
The morphology of the transdermally administrable ultrasound-responsive lipid drug carrier prepared in the present invention was observed using a Transmission Electron Microscope (TEM), and it was found to be spherical and to have a particle size of about 200nm (see fig. 1). And the particle size distribution (see fig. 2) and zeta potential (see fig. 3) of the lipid drug carrier were measured using a laser particle size analyzer, and it was found from the particle size distribution of fig. 2 that the particle size was about 200nm, which was compatible with TEM results, and that the particle size was suitable for transdermal administration, and that no significant change in the particle size or potential of the lipid drug carrier was observed from the seven-day-period particle size and zeta potential change patterns in fig. 3, indicating that it was stable for one week.
In order to observe the change condition of the lipid drug carrier under the action of ultrasound, the change of the lipid drug carrier within 60 minutes of ultrasound is observed in real time under an optical microscope. As can be seen from fig. 4, the ultrasonic response material in the carrier undergoes a phase change within 40 minutes of the application of ultrasonic irradiation, generates microbubbles and gradually breaks, and gradually disappears with the increase of the ultrasonic action time, so that the phase change process after 40 minutes is significantly weakened.
The above description is only of the preferred embodiments of the present invention, and is not intended to limit the present invention. Any simple modification, variation and equivalent variation of the above embodiments according to the technical substance of the invention still fall within the scope of the technical solution of the invention.
Claims (10)
1. A method of preparing a transdermally administrable ultrasound-responsive lipid drag carrier, comprising the steps of:
s1, dissolving lipid and a surfactant in an organic solvent, and uniformly mixing to obtain a mixed solution;
S2, placing the mixed solution obtained in the step S1 in a rotary evaporator, and removing the organic solvent under a vacuum condition to form a lipid film;
S3, adding a hydration solution into the lipid film obtained in the step S2, and standing for 8-16 hours to hydrate the film to obtain a hydrated film;
S4, placing the hydrated film obtained in the step S3 in an ice bath, performing ultrasonic treatment for 2-10 min under the condition of power of 30-150W to form a lipid drug carrier, then adding an ultrasonic response substance, continuing ultrasonic treatment for 2-10 min, filtering the obtained solution through a polycarbonate membrane to obtain the ultrasonic response lipid drug carrier capable of being subjected to transdermal drug delivery, and preserving at the temperature of lower than 4 ℃.
2. The method of claim 1, wherein the lipid in S1 is one or more of phosphatidylcholine, phosphatidylethanolamine or phosphatidylglycerol, the surfactant is one of Span 80, span 20, tween 80, tween 20, sodium cholate or sodium deoxycholate, and the mass ratio of the lipid to the surfactant is 70:30-95:5.
3. The method of claim 1, wherein the organic solvent in S1 is one or more of chloroform, methanol, ethanol, or dichloromethane.
4. The method according to claim 1, wherein the rotary evaporator in S2 has a temperature of 30 to 70 ℃ and a rotation speed of 60 to 90rpm.
5. The method of claim 1, wherein the hydration solution in S3 is deionized water or phosphate buffer.
6. The method according to claim 1, wherein the ultrasound responsive material in S4 is perfluorocarbon, in particular one or more of perfluoropentane or perfluorohexane, added in an amount of 1 (5-100) by volume ratio of perfluorocarbon to hydration solution.
7. The method of claim 1, wherein when the drug administered is a water-soluble drug, the water-soluble drug is dissolved in the hydration solution of step S3.
8. The method according to claim 1, wherein when the drug administration is a fat-soluble drug, the fat-soluble drug is dissolved in the organic solvent of step S1.
9. A transdermally administrable ultrasound-responsive lipid drag carrier prepared by the method of any one of claims 1 to 8.
10. Use of a transdermally administrable ultrasound-responsive lipid drag carrier according to claim 9 for the dermal delivery and deep administration of water-soluble or fat-soluble drugs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202510057442.8A CN119837832A (en) | 2025-01-14 | 2025-01-14 | Ultrasound responsive lipid drug carrier capable of percutaneous administration and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202510057442.8A CN119837832A (en) | 2025-01-14 | 2025-01-14 | Ultrasound responsive lipid drug carrier capable of percutaneous administration and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119837832A true CN119837832A (en) | 2025-04-18 |
Family
ID=95372741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510057442.8A Pending CN119837832A (en) | 2025-01-14 | 2025-01-14 | Ultrasound responsive lipid drug carrier capable of percutaneous administration and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN119837832A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1943541A (en) * | 2006-10-18 | 2007-04-11 | 许川山 | Supersonic micro bubble skin permeate promotor |
| JP2012036095A (en) * | 2010-08-03 | 2012-02-23 | Nippon Rikagaku Yakuhin Kk | Composition for sonoporation, and percutaneous drug delivery system |
| CN103751106A (en) * | 2013-11-27 | 2014-04-30 | 上海纳米技术及应用国家工程研究中心有限公司 | Water-soluble perfluorooctyl bromide-liposome nanosphere and preparation method thereof |
-
2025
- 2025-01-14 CN CN202510057442.8A patent/CN119837832A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1943541A (en) * | 2006-10-18 | 2007-04-11 | 许川山 | Supersonic micro bubble skin permeate promotor |
| JP2012036095A (en) * | 2010-08-03 | 2012-02-23 | Nippon Rikagaku Yakuhin Kk | Composition for sonoporation, and percutaneous drug delivery system |
| CN103751106A (en) * | 2013-11-27 | 2014-04-30 | 上海纳米技术及应用国家工程研究中心有限公司 | Water-soluble perfluorooctyl bromide-liposome nanosphere and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| MUNEERA JASMIN K P，等: "Transferosomes For Effective Transdermal Drug Delivery", INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES REVIEW AND RESEARCH, vol. 84, no. 4, 15 April 2024 (2024-04-15), pages 10 * |
| 陈桐楷;林华庆;李园;: "柔性纳米脂质体经皮给药新载体的研究进展", 中国药师, vol. 12, no. 06, 30 June 2009 (2009-06-30), pages 732 - 733 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Morrow et al. | Innovative strategies for enhancing topical and transdermal drug delivery | |
| Zhang et al. | Polymeric nanoparticles based on carboxymethyl chitosan in combination with painless microneedle therapy systems for enhancing transdermal insulin delivery | |
| Zhang et al. | Breaking the skin barrier: achievements and future directions | |
| CN107405313A (en) | The soluble micropin of insoluble drug transmission | |
| US20240366921A1 (en) | Microneedle patch for immunostimulatory drug delivery | |
| KR20170000745A (en) | Soluble microneedle patch for photosensitizer delivery | |
| CN105106024A (en) | Flexible nano-liposome freeze-dried powder prepared by cistanche tubulosa extract phenylethanoid glycosides and preparation method thereof | |
| EP3946258A1 (en) | Fluorouracil-containing formulations | |
| Kamboj et al. | Recent advances in permeation enhancement techniques for transdermal drug delivery systems: a review | |
| TW201714611A (en) | Soluble microneedle for insoluble drug delivery | |
| CN109820824B (en) | A kind of capsaicin liquid crystal nano spray preparation for promoting skin wound healing and preparation method thereof | |
| Neves Borgheti-Cardoso et al. | Topical and transdermal delivery of drug-loaded nano/microsystems with application of physical enhancement techniques | |
| CN119925273A (en) | A nano lipid mass transfer body for efficiently loading plant active ingredients and its preparation method and application | |
| CN108697639B (en) | A kind of percutaneous absorption composition and its use in preparing percutaneous absorption preparation | |
| CN119837832A (en) | Ultrasound responsive lipid drug carrier capable of percutaneous administration and preparation method thereof | |
| BR112016004372B1 (en) | method for removing a tattoo on a skin area and composition for removing or lightening a tattoo | |
| CN111297806A (en) | Salidroside transdermal whitening preparation based on vesicle carrier and preparation method and application thereof | |
| WO2023226136A1 (en) | Microneedle system for diagnosis and treatment of brain diseases and preparation method therefor | |
| Imam et al. | Penetration-enhancement strategies for dermal and transdermal drug delivery: an overview of recent research studies and patents | |
| Gujarathi et al. | Micro-and nano-systems in transdermal drug delivery | |
| Gupta et al. | Penetration enhancers: Role in transdermal drug delivery system | |
| Saadallah et al. | Strategies To Enhance Transdermal Drug delivery | |
| Upasani et al. | Innovations and future prospects of dermal delivery systems | |
| Aujla et al. | Comparative potential of vesicular carriers for transdermal drug delivery: A review | |
| RU2481822C1 (en) | Microemulsive compositions for creation of transdermal and transmucosal forms of pharmaceutical medications and cosmetic preparations, and method of their application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |